Wuxi Biologics (Cayman) (2269N) Revenue
Wuxi Biologics (Cayman) Revenue
Wuxi Biologics (Cayman) had a revenue of 11.79B in the quarter ending Jun 30, 2026, with -0.42%. This bring the company's revenue in the last twelve months to 23.62B, Increased 8.42%. In the fiscal year ending Dec 31, 2025, Wuxi Biologics (Cayman) had annual revenue of 21.79B with 16.68% growth.
- Revenue (ttm)
- 23.62B
- Revenue Growth
- 10.66%
- P/S Ratio
- 20.13
- Revenue/Employee
- MXN 1,481,810
- Employees
- 14,705
- Market Cap
- MXN 438.61B
Revenue Chart
Wuxi Biologics (Cayman) Revenue - Annual
Revenue History
| Fiscal End Date | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 21.79B | 3.11B | 16.68% |
| Dec 31, 2024 | 18.68B | 1.64B | 9.63% |
| Dec 31, 2023 | 17.03B | 1.77B | 11.56% |
| Dec 31, 2022 | 15.27B | 4.98B | 48.38% |
| Dec 31, 2021 | 10.29B | 4.68B | 83.35% |
| Dec 31, 2020 | 5.61B | 1.63B | 40.88% |
| Dec 31, 2019 | 3.98B | 1.45B | 57.18% |
| Dec 31, 2018 | 2.53B | 915.62M | 56.56% |
| Dec 31, 2017 | 1.62B | ― | ― |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company | Revenue |
|---|---|
| MX:2269N | 23.62B |